University Hospital Waterford

The Oncology department is running a broad portfolio of studies focused on neoplasms, with work spanning breast cancer, ovarian cancer, lung cancer, prostate cancer, and melanoma. These trials are designed to test new treatment strategies, compare therapies, and improve long-term outcomes for people with both early and advanced disease.

• Studies in breast cancer are evaluating ways to improve recurrence prevention, personalize treatment, and manage side effects linked to endocrine therapy.
• Research in ovarian cancer is examining maintenance approaches and new options for platinum-resistant disease.
• Trials in lung cancer, including non-small cell lung cancer, are testing immunotherapy- and targeted therapy-based approaches to extend survival and delay progression.

Overall, the site’s cancer research aims to refine treatment selection, strengthen disease control, and support more effective care across a wide range of solid tumors.

A major area of activity at University Hospital Waterford is breast cancer research, especially for HR-positive and HER2-negative disease. The trials are looking at whether adding new therapies can improve invasive disease-free survival, reduce relapse risk, and better tailor treatment for patients with early or metastatic disease.

• Research includes early breast cancer, metastatic breast cancer, and high-risk disease after standard treatment.
• Several studies are testing whether treatment can be guided by tumor biology to better match therapy with individual risk.
• Other work is focused on easing vasomotor symptoms caused by cancer treatment.

This program reflects a strong focus on improving both cancer control and quality of life for people living with breast cancer.

The site is also active in gynecologic oncology, with studies in ovarian cancer, cervical cancer, and related female urogenital diseases. These trials are exploring new ways to maintain remission, overcome treatment resistance, and improve disease control in advanced or recurrent settings.

• Trials include platinum-sensitive and platinum-resistant ovarian cancer, as well as fallopian tube and primary peritoneal cancers.
• Studies in cervical cancer are evaluating new treatment options for recurrent, stage IVB, and advanced disease.
• The research aims to improve survival and offer better options after standard therapy.

This is an important part of the oncology portfolio at University Hospital Waterford, especially for cancers where durable control remains challenging.

Another key area is respiratory tract diseases, particularly non-small cell lung cancer. The trials here are investigating whether newer immunotherapy and targeted treatment combinations can improve outcomes after surgery or in advanced disease.

• Studies are focused on early-stage NSCLC, advanced NSCLC, and disease with specific genetic features.
• Research is testing whether new treatment combinations can delay progression and improve survival.
• The work also includes approaches for patients who have already received standard treatment.

These studies highlight a strong effort to bring more precise and effective options to people with lung cancer.

University Hospital Waterford is conducting trials in hemic and lymphatic diseases, including acute myeloid leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, and multiple myeloma. The research is aimed at improving response rates, prolonging remission, and finding better treatment approaches for newly diagnosed or previously treated patients.

• Studies in AML are examining new combinations for patients who are not suitable for intensive chemotherapy.
• Trials in CLL and SLL are exploring ways to personalize treatment duration and improve disease control.
• Research in multiple myeloma and lymphoma is testing whether newer regimens can deepen responses.

This area of research reflects a broad commitment to advancing care for complex blood cancers.

Beyond oncology, the site includes trials in immune system diseases, pathological conditions, and other non-cancer conditions such as immunoglobulin A nephropathy, chronic inflammatory demyelinating polyneuropathy, and respiratory tract infection. These studies are focused on evaluating new therapies, reducing disease activity, and improving recovery and long-term outcomes.

• Kidney research is assessing treatments for IgA nephropathy with the goal of reducing protein loss and protecting renal function.
• Neurology-focused work in CIDP is looking at relapse prevention and symptom control.
• Acute care research is examining better management strategies for hospitalized patients with respiratory infections.

These studies show that University Hospital Waterford supports a wider clinical research environment alongside its strong cancer portfolio.